- PRECISION SMALL-MOLECULE THERAPEUTICS
Precision small molecules against Alzheimer’s disease.
Ultimate Medicine designs first-in-class small molecules that block the enzyme driving cognitive decline — targeting the biochemistry of the disease at its origin.
An overlooked driver of Alzheimer's disease - a microbially produced effector, switched off by precision chemistry.
At Ultimate Medicine, we are advancing a new class of first-in-class small molecules that block the enzyme behind cognitive decline, stopping the disease before it begins
A new class of therapeutics targeting BM01
Our small molecules selectively inhibit the bacterial enzyme that produces BM01 - preventing the effector from ever reaching the concentration that drives disease.
The MiDE Framework
From a general principle to a precision therapy for Alzheimer's.
MiDE — the Microbiome-Derived Effector framework — describes how a molecule made by gut bacteria can become a biochemical driver of disease. We follow that logic from its broadest form down to a single, addressable target in Alzheimer's.
01 ACROSS DISEASE
Microbes make effectors
Bacteria in the gut produce small effector molecules that enter circulation and signal throughout the body.
02 MECHANISM
Effectors become drivers
Above a critical concentration, an effector stops being benign and begins to actively drive disease biology.
03 Indication · Alzheimer's
BM01 drives cognitive decline
In Alzheimer's, the effector is BM01. We block the enzyme that makes it — holding BM01 below threshold.
MECHANISM
Keep BM01 below the threshold, and cognition is protected.
Cognitive decline begins once circulating BM01 crosses a critical threshold. Our small molecules inhibit its biosynthesis — holding levels in the safe range over time.
One enzymatic target.
A platform with reach across neurological disease - starting with Alzheimer's.
— TEAM
Join who?
The people building Ultimate Medicine — drug hunters, biochemists and clinicians turning the MiDE framework into medicine.
Antal Szalay, MD, MBA
Jerry Clifford, PhD, MBA
Senior strategy and commercialization executive with 20+ years across biotech and life sciences, former Danaher innovation executive and multi-venture founder with €200M+ in cumulative exit value.
Christophe Loeffler, MSC
Founding physician-scientist CEO advancing first-in-class gut–brain metabolite therapeutics, co-inventor of foundational IP published in Nature Aging and Nature Neuroscience.
Kevin McAllister, PhD, MBA
CNS drug development veteran with 25+ years advancing neuroscience programs from discovery through Phase 2, including multiple clinical proofs-of-concept at Novartis.
Lauren Moores, PhD
Data and AI executive building scalable information systems, data products, and innovative client solutions, with 25+ years of experience applying emerging technologies across complex industries.
Preston Campbell III, MD
Antal Szalay, MD, MBA
Belén Fortes, MBA
Strategic programs leader with a proven track record of securing $70M+ in biotech funding and driving execution from development through commercialization.
Robert Gallatto
We are hiring for MSCA Postdoctoral Fellowships!
Join Ultimate Medicine and the University of Freiburg to advance novel therapies for Alzheimer’s disease and related dementias. radd link to job description here